Lecap Asset Management Ltd. Invests $2.71 Million in Bruker Corporation (NASDAQ:BRKR)

Lecap Asset Management Ltd. bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 65,013 shares of the medical research company's stock, valued at approximately $2,714,000.

A number of other large investors also recently added to or reduced their stakes in BRKR. Quadrant Capital Group LLC raised its position in shares of Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after acquiring an additional 196 shares during the period. Insigneo Advisory Services LLC raised its position in shares of Bruker by 4.7% in the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock valued at $286,000 after acquiring an additional 218 shares during the period. Arizona State Retirement System raised its position in shares of Bruker by 0.7% in the 4th quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company's stock valued at $1,801,000 after acquiring an additional 222 shares during the period. CIBC Asset Management Inc increased its stake in Bruker by 5.6% during the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company's stock worth $248,000 after purchasing an additional 223 shares in the last quarter. Finally, CGN Advisors LLC raised its holdings in Bruker by 1.4% during the 1st quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company's stock worth $919,000 after buying an additional 296 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bruker

In other news, CEO Frank H. Laukien bought 2,608 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average cost of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer now owns 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 27.30% of the stock is owned by company insiders.

Bruker Stock Down 0.9%

Shares of BRKR traded down $0.38 during mid-day trading on Friday, hitting $41.80. 5,247,913 shares of the company's stock were exchanged, compared to its average volume of 1,697,550. The company has a market cap of $6.33 billion, a PE ratio of 80.38, a P/E/G ratio of 2.83 and a beta of 1.16. Bruker Corporation has a 52 week low of $34.10 and a 52 week high of $72.94. The company has a 50-day simple moving average of $38.52 and a 200 day simple moving average of $46.59. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The company had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. During the same period last year, the business earned $0.53 EPS. The business's quarterly revenue was up 11.0% on a year-over-year basis. On average, research analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 annualized dividend and a dividend yield of 0.48%. Bruker's dividend payout ratio is presently 38.46%.

Analysts Set New Price Targets

Several analysts have commented on BRKR shares. Stifel Nicolaus dropped their target price on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. Barclays dropped their target price on shares of Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. UBS Group dropped their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Bank of America dropped their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday. Finally, The Goldman Sachs Group dropped their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $52.89.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.